ArticlePacific Symposium on Biocomputing. Pacific Symposium on Biocomputing2025
Uncovering Important Diagnostic Features for Alzheimer's, Parkinson's and Other Dementias Using Interpretable Association Mining Methods.
Article in Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Untargeted Lipidomic Reveals Potential Biomarkers in Plasma Samples for the Discrimination of Patients Affected by Parkinson's Disease.Molecules (Basel, Switzerland) · 2025Article
- Integrating Social Determinants of Health in a Multi-Modal Deep Clustering Survival Model for Injury-Risk in Alzheimer's and Related Dementia Patients.Proceedings of machine learning research · 2025Article
- Determining the Importance of Clinical Modalities for NeuroDegenerative Disorders and Risk of Patient Injury Using Machine Learning and Survival Analysis.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Alzheimer's Disease and Related Dementias (ADRD) afflict almost 7 million people in the USA alone. The majority of research in ADRD is conducted using post-mortem samples of brain tissue or carefully recruited clinical trial patients. While these resources are excellent, they suffer from lack of sex/gender, and racial/ethnic inclusiveness. Electronic Health Records (EHR) data has the potential to bridge this gap by including real-world ADRD patients treated during routine clinical care. In this study, we utilize EHR data from a cohort of 70,420 ADRD patients diagnosed and treated at Penn Medicine. Our goal is to uncover important risk features leading to three types of Neuro-Degenerative Disorders (NDD), including Alzheimer's Disease (AD), Parkinson's Disease (PD) and Other Dementias (OD). We employ a variety of Machine Learning (ML) Methods, including uni-variate and multivariate ML approaches and compare accuracies across the ML methods. We also investigate the types of features identified by each method, the overlapping features and the unique features to highlight important advantages and disadvantages of each approach specific for certain NDD types. Our study is important for those interested in studying ADRD and NDD in EHRs as it highlights the strengths and limitations of popular approaches employed in the ML community. We found that the uni-variate approach was able to uncover features that were important and rare for specific types of NDD (AD, PD, OD), which is important from a clinical perspective. Features that were found across all methods represent features that are the most robust.
Indexed as
Identifiers
39670401PMC11649014What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.